Obesity and female fertility: a primary care perspective

Scott Wilkes, Alison Murdoch

Abstract
Infertility affects approximately one in six couples during their lifetime. Obesity affects approximately half of the general population and is thus a common problem among the fertile population. Obese women have a higher prevalence of infertility compared with their lean counterparts. The majority of women with an ovulatory disorder contributing to their infertility have polycystic ovary syndrome (PCOS) and a significant proportion of women with PCOS are obese. Ovulation disorders and obesity-associated infertility represent a group of infertile couples that are relatively simple to treat. Maternal morbidity, mortality and fetal anomalies are increased with obesity and the success of assisted reproductive technology (ART) treatments is significantly reduced for obese women. Body mass index (BMI) treatment limits for ART throughout the UK vary. The mainstay for treatment is weight loss, which improves both natural fertility and conception rates with ART. The most cost-effective treatment strategy for obese infertile women is weight reduction with a hypo-caloric diet. Assisted reproduction is preferable in women with a BMI of 30 kg/m² or less and weight loss strategies should be employed within primary care to achieve that goal prior to referral.

Keywords: family practice, infertility, obesity, polycystic ovary syndrome, primary care

Introduction
Obesity is an increasing problem encountered by general practitioners (GPs) and its impact on fertility is significant. Approximately half of the USA, UK, European and Australian population are overweight or obese. In the UK, the GP contract, through the Quality and Outcomes Framework (QOF) points system, encourages GPs to identify obese patients in their practice population. However, to date there is no contractual obligation upon GPs to manage their obese population. National Institute for Health and Clinical Excellence (NICE) guidelines for the management of obesity focus upon environmental strategies and drug therapies. Despite these guidelines there is only modest evidence to suggest nurse-led intervention and follow-up can achieve a sustained weight loss of 3 kg at 1 year. General practice may have a significant contribution to make to the management of obesity and the infertile obese population. This paper reviews the impact of obesity upon female fertility from a primary care perspective, reviewing policy and practice guidelines, effect of obesity upon conception rates, health risks, economic costs and management strategies for the obese infertile population.

Literature search
MEDLINE and PubMed searches were carried out for the period July 1998 to June 2008 with the following search terms: ‘infertility, female’ and ‘obesity’. A total of 61 citations were found. In addition, the reference lists of the papers were reviewed and relevant articles sought. A search of the Cochrane Database revealed no directly relevant systematic reviews. NICE guidance on Obesity: The Prevention, Identification, Assessment and Management of Overweight and Obesity in Adults and Children and Fertility: Assessment and Treatment for People with Fertility Problems were reviewed.

Obesity and fertility in context
Obesity represents a significant cause of infertility, its negative effect having been recognised since the days of Hippocrates:

“The girls get amazingly flabby and podgy … People of such constitution cannot be prolific … fatness and flabbiness are to blame. The womb is unable to receive the semen and they menstruate infrequently and little. As good proof of the sort of physical characteristics that are favourable to conception, consider the case of serving wenches. No sooner do they have intercourse with a man than they become pregnant, on account of their sturdy physique and their leanness of flesh.”

More recently, oligo-ovulation, obesity and hyperandrogenism were recognised with the eponymous syndrome of Stein and Leventhal characterised by oligomenorrhea, obesity and hirsutism. However, the current obesity epidemic is largely diet/lifestyle-related.

A simple method of assessing obesity is body mass index (BMI) (Table 1) although BMI is not universally appropriate and does not take account of central adiposity or ethnic variation. Waist circumference would be more accurate in, for example, Asians and body builders. Estimates of obesity and overweight throughout European countries vary between 30% and 80%. Approximately 15% of women undergoing ART are overweight or obese.
Obesity has an impact on many aspects of reproductive health. In relation to fertility, it is most commonly associated with polycystic ovary syndrome (PCOS).

**Simple obesity and PCOS**

Fertility is adversely affected by simple obesity, PCOS and particularly in obese women with PCOS. One quarter of all infertile couples have an ovulatory disorder and 90% of those women with an ovulatory disorder have PCOS. Most women with PCOS are overweight, with estimates of the prevalence of obesity in PCOS ranging from 35% to 65%. Whilst not all women with PCOS are obese, PCOS is associated with a disorder of energy balance, which predisposes to obesity. Notwithstanding this predisposition, which is often used by patients as an excuse for weight reduction failure, obesity in those with PCOS is often the result of diet and not the endocrine disorder. Of all women of reproductive age, up to 10% have PCOS.

Simple obesity and PCOS are associated with the development of hyperinsulinaemia and hyperandrogenism. The related chronic anovulation leads to decreased fertility.

Simple obesity is associated with many medical conditions including type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, sleep apnoea, breast cancer, uterine cancer, PCOS and the metabolic syndrome. Abdominal adiposity and insulin resistance are features of simple obesity. Insulin resistance and hyperinsulinaemia play a pivotal role in the infertility of obese patients. Insulin stimulates steroidogenesis in the ovary resulting in raised serum androgens and also decreases liver synthesis of sex hormone binding globulin (SHBG), the carrier protein for sex steroid hormones. Adipose tissue stores excess sex steroids, which are readily available and raise plasma androgens. The above mechanisms have a deleterious effect upon the ovulatory capacity of the ovary.

PCOS is the most common endocrine disorder affecting women characterised by oligo- and/or anovulation, clinical and/or biochemical signs of hyperandrogenism and polycystic ovaries. It is the excess androgen production that is thought to contribute to abnormal secretion of luteinising hormone, abdominal adiposity and insulin resistance. PCOS is believed to have a genetic predisposition that is exacerbated by obesity. Androgen excess in utero may also be responsible for programming and the subsequent development of PCOS. Whilst weight reduction of obese women with PCOS falls within the remit of the generalist, the management of PCOS per se is challenging, should be symptom orientated and performed by those with expertise.

**Policy and practice guidelines**

The British Fertility Society (BFS) recommends that women should aim for a normal BMI before starting any form of fertility treatment. Specifically, it advises deferring treatment until the BMI is less than 35 kg/m² and treatment is preferable with a BMI of 30 kg/m² or less. Assisted reproductive technology (ART) treatments offered to obese women in fertility clinics throughout the UK vary. For example, differing BMI limits are applied between fertility units for in vitro fertilisation (IVF) treatment but also differing BMI limits are applied within units related to access to IVF and clomifene treatment. Fifty per cent of licensed ART units apply BMI limits to clomifene treatment and 70% to ART treatments. Those limits vary between 25 and 40 kg/m². There is also variation in the approach of fertility units in the treatment of obesity, with 20% of units using orlistat as part of a weight reduction programme and 50% using metformin to overcome insulin resistance encountered in simple obesity and obese women with PCOS. The ethical issues in imposing BMI treatment limits for obese women are those of informed patient choice, health risks, success rates and private practice of licensed fertility units. By imposing BMI treatment limits we are removing patient autonomy and informed decision making by the infertile couple. Should obese women have the right to choose a course of action, assuming that course of action is fully informed, that puts themselves and their unborn child at risk? After all, normally fertile obese women do have the right to, and do become pregnant. Whilst it has been acknowledged that BMI treatment limits provide a tool for National Health Service (NHS) rationing of fertility treatments, the arguments for imposing BMI limits are patient safety, improved conception rates, both naturally and with ART.

**Effect of obesity on conception rates**

The conception rates for the normal fertile population is approximately 30% per cycle with a cumulative success rate of 84% at 1 year. Similar success rates of 30% per cycle are also typical with ART. Women with simple obesity have reduced fertility and experience lower success rates per cycle. The success of ART in obese women is significantly reduced when compared with non-obese women. These lower success rates with ART are associated with central adiposity and ART becomes less successful with increasing obesity.

Women with PCOS who are obese menstruate less frequently and are less likely to respond to ovulation induction when compared with their lean counterparts. However, weight reduction in obese women with PCOS profoundly increases their chance of conception both spontaneously and with ovulation induction.

**Health risks for obese infertile women**

Maternal mortality is increased in obesity. In the 2002 Confidential Enquiry into Maternal and Child Health, 35% of the women who died were obese. Obesity is responsible for 80% of anaesthetic-related deaths and 18% of obstetric deaths. Obesity carries a greater risk of gestational diabetes, thromboembolism, hypertension and Caesarean section. Obese women with PCOS require higher doses of gonadotrophins to stimulate ovulation in ART cycles compared with their lean counterparts. Obese women with PCOS are more difficult to monitor with ultrasound, and carry an increased risk of ovarian hyperstimulation syndrome and multiple pregnancies. There is a greater risk of miscarriage in obese women, which is reversed with weight loss. Other risks include congenital anomalies, including neural tube defects and cardiac malformations, and intrapartum problems.

Maternal obesity is increasing and accelerating and has been shown to be associated with socioeconomic deprivation.
Economic costs of obese infertile women

In an economic evaluation in Australian women, 67 anovulatory women received fertility treatment at a cost of $550 000 to achieve two live births. The same women then underwent a lifestyle programme including a hypo-caloric diet and exercise resulting in 45 babies and a cost of $210 000. In simple terms, the weight loss programme resulted in a cost per child reduction from $275 000 to $4700. However a recent cross-sectional survey of 1756 women in a tertiary care fertility unit demonstrated no difference in the cost per live birth resulting from IVF when comparing underweight, overweight and obese class I to women with normal BMI.6 The authors did recommend weight reduction to reduce obstetric complications. Additionally obese mothers cost five times more to look after compared with their lean counterparts.47 Nurse-led primary care weight management in the UK has been shown to be effective and 8% of the programme costs are recouped by the subsequent non-prescription of drugs.48 Assuming resumption of ovulation44 a significant proportion will not proceed to ART following spontaneous conception thus giving further cost savings.

Management of anovulation in obese infertile women

Weight loss is key to the management of obesity-related anovulation. The BFS recommend assistance with weight loss using psychological support, dietary advice, exercise classes and, where appropriate, drug therapy or bariatric surgery.22 The first-line treatment of obese infertile women with or without PCOS is lifestyle intervention including a hypo-caloric diet.17 Weight loss results in a reversal of the obesity-associated adverse biochemical profile with decreased insulin resistance and a resumption of menstrual regularity and ovulatory function.17 Moderate weight loss and a reduction in abdominal obesity improves menstrual regularity, ovulation and subsequent fertility in obese women.16 As little as a 5–10% reduction in BMI in obese infertile women results in improvement in outcome for all forms of fertility treatment.65 Clark et al.34 demonstrated that a weight loss of 14 lbs (approximately 6% of initial body weight) is associated with resumption of ovulation in some anovulatory women and an increase in pregnancy rate. A similar observation occurs with weight loss in obese women with PCOS34,44,49 as well as an improvement in biochemical markers with increased SHBG and reduced serum testosterone.33,49,50 Dietary treatment of obesity aims to increase calorie expenditure over calorie intake. This is best achieved by combining exercise with a reduction in calorie intake of approximately 500 calories per day with only 30% of daily calories coming from fat.16 Peer group support has been shown to be successful in reducing weight and improving pregnancy rates for obese infertile women.51 Patients are reluctant to present to their GP with concerns about their weight; they perceive there is little or no NHS support for weight management and feel stigmatised.52 They are, however, aware of their own responsibilities for weight management and feel primary care is the best place to deliver the service,52 but primary care staff are disillusioned with the lack of success in the general obese population and lack of successful interventions available.53 Nevertheless, obese infertile women represent a cohort of patients more motivated and receptive to weight reduction strategies employed within general practice.

Drug therapy should be considered as adjunctive therapy with lifestyle modification and hypo-caloric dieting.12,17,54 Pharmacotherapies aimed primarily at weight reduction include orlistat, sibutramine and rimonabant. Sibutramine and rimonabant are not recommended for women trying to conceive. Insulin-sensitising agents such as metformin, commonly used in the treatment of type 2 diabetes mellitus, may decrease plasma insulin and associated hyperandrogenism but its role in anovulatory PCOS remains unclear.22,55 The glitazone family of drugs also decrease insulin and circulating androgens, but there is no trial evidence to show their effect in humans on obesity-related infertility.17 Clomifene is an effective ovulation induction agent but its effect is severely reduced in the obese patient56 and its use in obesity-related anovulation should be reserved for use by fertility specialists. There are limited data suggesting improved reproductive function following bariatric surgery.57 However surgical intervention may be warranted to prevent potential adverse outcomes of pregnancy in obese women.58 Bariatric surgery remains a third-line treatment option. The biggest challenge, however, is to prevent the 90% of people who successfully lose weight from relapsing.59

Conclusions

The prevalence of obesity is increasing and with it ovulatory dysfunction and female infertility. Establishing a diagnosis of anovulation in obese women in general practice is relatively straightforward. The most cost-effective treatment for anovulation in obese infertile women is weight loss. Weight loss should be promoted as the best treatment for the obese infertile woman with menstrual irregularity and ovulatory infertility.16 Support for these patients in general practice should aim to reduce weight until resumption of ovulation; this may be as little as a 5–10% reduction in BMI for some women. NICE and the BFS recommend reducing BMI to below 30 kg/m² before inducing ovulation with clomifene or gonadotrophins.4 It is the authors’ experience that obese infertile women are commonly referred back to primary care for weight management. For the NHS, primary care may be the best place to adopt weight management strategies for the infertile couple16 with clinical guidelines to support this role2 and modest evidence demonstrating clinically significant weight loss.3 Currently the GP QOF system ensures that practices can produce a register of patients aged 16 years and over with a BMI ≥30 kg/m² in the last 15 months. The management of this cohort is variable. Some practices offer dietary advice and support; others advocate private support (e.g. WeightWatchers®) while some Primary Care Trusts and local Councils invest in exercise programmes in local gymnasia for example. A more recent useful resource that general practice can direct obese patients to is the NHS ‘Change for Life’ website.60 All of these strategies aim to reduce calorie intake and increase calorie expenditure.

Obese women should be encouraged to lose weight for three reasons: first, there is a significant chance of recovery of natural fertility; second, ART procedures are more likely to succeed; and third, maternal morbidity and mortality will be reduced. Doctors may insist on weight reduction, which is a proven therapeutic option to improve fertility and also reduce the associated risks to both mother and unborn child. In line with the BFS recommendation the authors suggest that assisted reproduction is preferable in women with a BMI of 30 kg/m² or less and weight loss strategies should be employed within primary care to achieve that goal prior to referral.
Statements on funding and competing interests

Funding
The authors would like to acknowledge the NHS National Coordinating Centre for Research Capacity Development who funded this work through a National Institute for Health Research (NIHR) award held by Dr Scott Wilkes; Primary Care Researcher Development Award, National Coordinating Centre for Research Capacity Development, Leeds Innovation Centre, 103 Clarendon Road, Leeds, LS1 3JB, UK. All the researchers involved in the production of this paper are independent from the funder.

Competing interests
None identified.

References

War is a great horror. All right-thinking people agree on this. War has brought more misery to humanity than any other single thing. Why, then, do we as a species indulge in it so often and so easily? This question has never been as urgent as it is today. The world has never been more fractious and humankind’s ability to destroy itself gives the lie. The reasons that were given by the war lords who went before them are rapidly dropped and changed when they wore thin. An open-minded person could only conclude that the UK and the USA wanted to go to war. In answering why this dark desire exists, Potts and Hayden offer a way of defusing it. Their thesis is an intriguing one – enhance the role of women; give them a greater part in society, more control over their own lives, and the rate at which they reproduce. This amounts to an effective curb of the dark impulse – and here lies the rationale for readers of this journal having not only an interest but also potentially a role of women with polycystic ovary syndrome, a vital role to play, in the prevention of war.

Nothing less.

Reviewed by Lester Venter
Freelance Writer, London, UK

BOOK REVIEW

SYLK natural personal lubricant for the alleviation of atrophic vaginitis is now included within the NHS Drug Tariff Part IX and available on an FP10.

Adopted and endorsed by a multi-professional group investigating the use of vaginal dilators following pelvic radiotherapy, as well as members of the National Committee of the National Forum of Gynaecology Oncology Nurses (NFGON) and other relevant groups within the NHS, SYLK:

- has a non chemical base derived from an extract of the kiwi fruit plant that effectively mimics a woman’s natural secretions and is the only paraben free lubricant
- has passed cytotoxicity, sensitisation and product stability tests. The pH of SYLK is controlled within 4.5 to 4.7, to equate with the vaginal environment
- is a class 1 medical device available in one 40ml size, sufficient for up to 150 applications

Free samples and consumer literature are readily available from:

SYLK Limited
FREEPOST, PO Box 340
Rickmansworth, WD3 5WD
Tel: 0870 950 6004
www.sylk.co.uk

Now available on an FP10

Marie Stopes International centres around the UK provide expert care and support for clients 24 hours. We are chosen by over 70 Primary Care Trusts to support their local sexual health services. For more information or a sexual health pack call

0845 120 3644
www.mariestopes.org.uk

We advise... you decide.

©FSRH J Fam Plann Reprod Health Care 2009: 35(3)